The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis

Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14–22.

Tefferi A, Thiele J, Orazi A, et al.: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092–1097.

Levine RL, Pardanani A, Tefferi A, et al.: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673–683.

Nelson ME, Steensma DP: JAK2 V617F in myeloid disorders: What do we know now, and where are we headed? Leuk Lymphoma 2006, 47:177–194.

Wadleigh M, Gilliland DG: The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: summary of published literature and a perspective. Curr Hematol Malig Rep 2006, 1:75–80.

Scott LM, Tong W, Levine RL, et al.: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459–468.

Levine RL, Wadleigh M, Cools J, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387–397.

Tefferi A, Vardiman JW: The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol 2007, 14:115–122.

Nussenzveig RH, Swierczek SI, Jelinek J, et al.: Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007, 35:32–38.

Spivak JL: Polycythemia vera: myths, mechanisms, and management. Blood 2002, 100:4272–4290.

Tefferi A: The diagnosis of polycythemia vera: new tests and old dictums. Best Pract Res Clin Haematol 2006, 19:455–469.

Pearson TC: Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001, 38:21–24.

Murphy S: Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999, 36:9–13.

James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144–1148.

Jones AV, Kreil S, Zoi K, et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162–2168.

Birgegard G, Wide L: Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol 1992, 81:603–606.

Mossuz P, Girodon F, Donnard M, et al.: Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004, 89:1194–1198.

Dobo I, Donnard M, Girodon F, et al.: Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera. Hematol J 2004, 5:161–167.

Gruppo Italiano Studio Policitemia: Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995, 123:656–664.

Ruggeri M, Tosetto A, Frezzato M, et al.: The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003, 139:470–475.

Thiele J, Kvasnicka HM, Diehl V: Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005, 113:213–219.

Jantunen R, Juvonen E, Ikkala E, et al.: Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol 1999, 78:219–222.

Shih LY, Lee CT: Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 1994, 83:744–748.

Georgii A, Buesche G, Kreft A: The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998, 11:721–749.

Thiele J, Kvasnicka HM: Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005, 20:317–328.

Thiele J, Kvasnicka HM, Muehlhausen K, et al.: Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract 2001, 197:77–84.

Ellis JT, Peterson P, Geller SA, et al.: Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986, 23:144–155.

Thiele J, Kvasnicka HM, Vardiman J: Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006, 19:413–437.

Barosi G, Mesa RA, Thiele J, et al.: Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008, 22:437–438.

Murphy S, Peterson P, Iland H, et al.: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997, 34:29–39.

Lengfelder E, Hochhaus A, Kronawitter U, et al.: Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998, 100:15–23.

Sacchi S, Vinci G, Gugliotta L, et al.: Diagnosis of essential thrombocythemia at platelet counts between 400 and 600×10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC). Haematologica 2000, 85:492–495.

Pardanani AD, Levine RL, Lasho T, et al.: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472–3476.

Thiele J, Kvasnicka HM: Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost 2006, 32:219–230.

Florena AM, Tripodo C, Iannitto E, et al.: Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004, 89:911–919.

Gianelli U, Vener C, Raviele PR, et al.: Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006, 47:1774–1781.

Kreft A, Buche G, Ghalibafian M, et al.: The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 2005, 113:137–143.

Barosi G: Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999, 17:2954–2970.

Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342:1255–1265.

Dingli D, Mesa RA, Tefferi A: Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med 2004, 43:540–547.

Pikman Y, Lee BH, Mercher T, et al.: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.

Thiele J, Kvasnicka HM: Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 2005, 32:380–394.

Dickstein JI, Vardiman JW: Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol 1993, 99:513–525.

Buhr T, Busche G, Choritz H, et al.: Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003, 119:152–158.

Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al.: Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003, 44:949–953.

Thiele J, Kvasnicka HM, Facchetti F, et al.: European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90:1128–1132.

Thiele J, Kvasnicka HM, Diehl V: Standardization of bone marrow features-Does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005, 20:633–644.

Wilkins BS, Erber WN, Bareford D, et al.: Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008, 111:60–70.

Manoharan A, Horsley R, Pitney WR: The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979, 43:185–190.

Spivak JL, Silver RT: The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal. Blood 2008, 112:231–239.